Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Staodyn

This article was originally published in The Gray Sheet

Executive Summary

Firm's board of directors approves the repurchase of up to 200,000 shares of common "as a result of what the company views as the depressed market price of its common stock," the electromedical treatment devices manufacturer announces. The board also extends to Feb. 28, 1995 the expiration date of the firm's currently outstanding warrants issued in June 1991 and expiring June 19, 1994. Two warrants can be used to buy one share of Staodyn common stock at $5 per share; 920,000 of these warrants are outstanding. The firm notes it has begun shipping its Dermapulse wound management system to Canada and expects to begin marketing the electrostimulation device in Europe within six months
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel